Funding Model

  • Allocations

    Under the Global Fund financing model, each eligible country is allocated a certain amount of funding for each disease component for which they are eligible – AIDS, tuberculosis and/or malaria – for a three-year allocation period. Each country’s Country Coordinating Mechanism can submit concept notes to access this funding during any submission “window” during that period.

    Allocations are approved by the Board of the Global Fund. In the 2014-2016 period, the amounts allocated to each country have been based on a combination of disease burden and the country’s ability to pay (income level). These initial amounts have then been adjusted based on a number of qualitative factors, including:

    • Previous grant performance
    • Impact
    • Increasing rates of infection
    • Absorptive capacity
    • Risk 

    Countries can make adjustments to how their overall allocation is divided among the diseases if needed, with the approval of the Global Fund. For example, a portion of the allocation for one disease can be used for another disease instead, or for many applicants some of the funding can be used to support health systems strengthening rather than a specific disease.

    To access the final 15 percent of their allocation, countries must demonstrate increased national funding commitments above and beyond what is required by the Global Fund’s counterpart financing policy. This is also known as “increasing future commitments” and formerly called “willingness to pay.” See Counterpart Financing for more.

    The amount of funding available for allocation to countries is based on how much money is raised through the Global Fund’s replenishment process. Using the total amount of funding pledged, the Global Fund determines the amount of resources expected to be available over the three-year period. Then, based on the Board decision that a specified percentage of all program funding should initially go to HIV and AIDS, TB and malaria, the Global Fund will announce how much total funding is available for each eligible country and disease.